4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $3M | -$24M | 94.4% | -956.5% | -$2973 | — | $4M |
| 2024 | $2M | $478561 | 91.8% | 33.3% | $874901 | — | $547498 |
| 2023 | $2M | $852042 | 87.4% | 48.0% | $103861 | — | $1M |
| 2022 | $2M | $191298 | 73.5% | 10.3% | $1M | — | — |
How the market has priced BYAH against its own fundamentals since 2025-10 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, Park Ha Biological Technology Co., Ltd.'s revenue has grown 9.6% per year. These are computed facts, not advice.
As of FY2025, Park Ha Biological Technology Co., Ltd. reported — of total debt against $4M of cash; operating income covered interest expense -588997.6×.
In FY2025, gross margin was 94.4%, operating margin -956.5%, and net margin -965.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.